A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
I4V-MC-JAHH - ClinicalTrials.gov - NCT02708095
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as baricitinib in participants with systemic lupus erythematosus.
Trial Summary
Age Range
≥18 yearsConditions the trial is for
Systemic Lupus ErythematosusWhat the trial is testing?
BaricitinibCould I receive a Placebo?
YesEnrollment Goal
314Trial Dates
Mar 24, 2016 - Nov 9, 2017How long will I be in the trial?
Your participation could last up to 34 weeks and include 10 visits to the study center.Trial Phase
IILilly Trial Alerts
Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
You will complete the questionnaire on another website.YesNo